---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-028167"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T07:33:31.593955+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sangamo Therapeutics Q3 net loss $53.2M; revenue down, Fabry gene therapy expands

## Summary
- Q3 net loss $53.2M ($0.34/shr) vs $47.7M ($0.33/shr) prior year; revenue $26.5M down from $28.6M.
- Cash $350.3M at Sep 30 (Dec 31: $464.7M); raised $75.1M net from ATM Jan-Oct 2022.
- FY2022 guidance narrowed: GAAP op expenses $315-325M, non-GAAP $280-290M (excl ~$35M SBC).
- Fabry gene therapy STAAR expansion: 5 patients dosed at 5e13 vg/kg, including first two females; Phase 3 prep ongoing.
- Hemophilia A (Pfizer) Phase 3 AFFINE trial recruitment resumed; pivotal readout expected H1 2024.

## SEC filing metadata
- accession: 0001628280-22-028167
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828022028167/0001628280-22-028167-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828022028167/sgmo-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-028167
- JSON: https://secwatch.observer/filing/0001628280-22-028167.json
- Plain text: https://secwatch.observer/filing/0001628280-22-028167.txt

## Key facts
- Earnings Releases
  SANGAMO THERAPEUTICS, INC reported third quarter ended September 30, 2022 results: revenue 26.5 million, net income 53.2 million (net loss), EPS 0.34 per share (net loss).
  - Period: third quarter ended September 30, 2022
  - Revenue: 26.5 million
  - Net income: 53.2 million (net loss)
  - EPS: 0.34 per share (net loss)
  - Result: reported results
  source text: Consolidated net loss for the third quarter ended September 30, 2022 was $53.2 million, or $0.34 per share, compared to a net loss of $47.7 million, or $0.33 per share, for the same period in 2021. Revenues Revenues for the third quarter ended September 30, 2022 were $26.5 million, compared to $28.6 million for the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001233/000162828022028167/0001628280-22-028167-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.